If you follow Alzheimer’s research or have been paying particular attention to the saga over aducanumab, the controversial treatment developed by Biogen, you know that this is a very important week. A panel of experts is convening to decide whether to recommend the Food and Drug Administration approve the drug, which would make it the first new Alzheimer’s treatment in nearly two decades.
But you should also know there is a lot of information to digest — both ahead of the Friday meeting and during it. In the days to come, we’re going to see hundreds of pages of supporting data, debatably legible tea leaves, and diametrically opposed comments from experts around the world.
I certainly hope Adam and Damian would be there to cover and report directly all the details preferably throughout the day continuously as befitting theirvincmvedtigstive journalism commitment!